Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Harvard Business School
Accenture
Federal Trade Commission
Chinese Patent Office
Queensland Health
Fish and Richardson
Teva
Novartis

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,119,093

« Back to Dashboard

Which drugs does patent 7,119,093 protect, and when does it expire?

Patent 7,119,093 protects OFEV and is included in one NDA.

This patent has forty-two patent family members in thirty-five countries.
Summary for Patent: 7,119,093
Title:3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-an- ilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulpho- nate and the use thereof as a pharmaceutical composition
Abstract: The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulpho- nate of formula I and the use thereof as a pharmaceutical composition ##STR00001##
Inventor(s): Roth; Gerald J. (Biberach, DE), Linz; Guenter (Mittelbiberach, DE), Sieger; Peter (Mittelbiberach, DE), Rall; Werner (Mittelbiberach, DE), Hilberg; Frank (Wien, AT), Bock; Thomas (Biberach, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/623,971
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,119,093

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,119,093

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 33 500Jul 24, 2002

International Patents Family Members for US Patent 7,119,093

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Saudi Arabia 1864 ➤ Subscribe
Serbia 52283 ➤ Subscribe
Serbia 20050046 ➤ Subscribe
Portugal 1527047 ➤ Subscribe
Poland 223758 ➤ Subscribe
Poland 372996 ➤ Subscribe
Peru 07042004 ➤ Subscribe
New Zealand 538367 ➤ Subscribe
Norway 330486 ➤ Subscribe
Norway 20050985 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
Healthtrust
UBS
Fish and Richardson
QuintilesIMS
Cipla
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot